Brian C. Gadbaw MD
Executive Medical Director - Pediatric Oncology Development - Novartis
Join to View Full Profile
1 Health PlazaEast Hanover, NJ 07936
Dr. Gadbaw is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Brian Gadbaw is a specialist in Pediatric Hematology and Oncology. He completed his medical education in 2004 at Michigan State University College of Human Medicine, followed by a residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology at the University of Wisconsin Hospitals and Clinics. Dr. Gadbaw has contributed to various publications on topics such as the efficacy and safety of ruxolitinib, a subject he has explored in collaboration with multiple journals including Cancer Chemotherapy and Pharmacology, Annals of Hematology, International Journal of Hematology, Immunotherapy, and Blood. His work is well-cited in the field. He currently leads Pediatric Oncology development within the Pediatric Center of a Excellence at Novartis.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Pediatric Hematology/Oncology, 2007 - 2010- University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 2004 - 2007
Michigan State University College of Human MedicineClass of 2004
Certifications & Licensure
WI State Medical License 2005 - 2011
Publications & Presentations
PubMed
- 19 citationsMultiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjectsVassilios Aslanis, Kenichi Umehara, Felix Huth, Taoufik Ouatas, Savita Bharathy
Cancer Chemotherapy and Pharmacology. 2019-07-19 - 20 citationsEfficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.Jean-Jacques Kiladjian, Paola Guglielmelli, Martin Griesshammer, Güray Saydam, Tamás Masszi
Annals of Hematology. 2018-02-02 - 10 citationsRuxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegalyKeita Kirito, Kenshi Suzuki, Koichi Miyamura, Masahiro Takeuchi, Hiroshi Handa
International Journal of Hematology. 2018-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
